Latest news with #TrinaSpear
Yahoo
5 hours ago
- Business
- Yahoo
FIGS Q1 Earnings Call: Growth Driven by U.S. Rebound and Brand Investments Amid Tariff Uncertainty
Healthcare apparel company Figs (NYSE:FIGS) reported Q1 CY2025 results beating Wall Street's revenue expectations , with sales up 4.7% year on year to $124.9 million. Its non-GAAP loss of $0 per share decreased from $0.01 in the same quarter last year. Is now the time to buy FIGS? Find out in our full research report (it's free). Revenue: $124.9 million vs analyst estimates of $119.2 million (4.7% year-on-year growth, 4.8% beat) Adjusted EBITDA: $9 million vs analyst estimates of $8 million (7.2% margin, 12.5% beat) Operating Margin: -0.2%, in line with the same quarter last year Active Customers: 2.7 million, up 99,000 year on year Market Capitalization: $838.8 million Figs' first quarter results reflected a return to positive growth in the U.S. and an uptick in average order value, as management emphasized normalization in healthcare apparel purchasing patterns. CEO Trina Spear noted, 'We saw continued signs that scrubwear trends are starting to normalize from the COVID overhang,' highlighting stronger gains during standard pricing periods and improved customer retention. The company also attributed performance to successful customer reactivation campaigns and increased full-price sales, resulting in record average order values. International sales maintained momentum, and non-scrubwear items like footwear and underscrubs experienced double-digit growth. Management pointed to disciplined marketing and inventory strategies, along with ongoing investments in fulfillment and supply chain operations, as key contributors to the quarter's outcomes. Looking ahead, management's outlook centers on mitigating the impact of newly imposed tariffs and adapting to ongoing macroeconomic uncertainty. CFO Sarah Oughtred stated, 'Our full year adjusted EBITDA outlook assumes the current 10% baseline and reciprocal tariffs on China remain in effect,' while emphasizing the company's focus on cost mitigation and selective investments in international expansion, business-to-business (B2B) sales, and retail stores. CEO Trina Spear indicated continued commitment to cautious promotional strategies and a deliberate approach to potential pricing actions, noting, 'We're focused on doing everything we can to offset the impact of the tariffs.' Management expects gross margins to remain stable in the near term, but anticipates higher cost pressures in the second half of the year as tariff effects flow through inventory. Figs plans to prioritize operational discipline while maintaining investments in growth initiatives. Management identified a rebound in U.S. demand, improved customer engagement, and ongoing supply chain investments as primary drivers of quarterly performance, while also outlining challenges from tariffs and evolving promotional strategies. U.S. customer reactivation: Management highlighted targeted efforts to bring back lapsed customers, supported by refreshed marketing campaigns and expanded product offerings, which contributed to the increase in active customers and a return to domestic sales growth. Product mix and limited editions: The quarter saw robust performance in limited edition scrubwear and new color launches, with management noting that higher average unit prices and a reduction in discounting drove average order value to a record high. International sales expansion: Figs continued to grow internationally, particularly in markets such as Mexico, Europe, and the Middle East, with plans to enter Japan and South Korea later in the year. Management cited localized marketing and community engagement as key factors in these regions. Supply chain and fulfillment center investments: The company is working to optimize its recently expanded fulfillment center, targeting greater cost efficiencies and scalability. Management believes these logistics improvements will support future growth and help offset tariff-related pressures. Tariff mitigation strategies: While acknowledging the potential cost impact of new tariffs, management outlined a multipronged response that includes renegotiating supplier contracts, adjusting inventory sourcing, and scrutinizing expense management. Pricing increases were described as a last resort, with the company preferring to maintain affordability for healthcare professionals. Figs' guidance for the remainder of the year is shaped by ongoing tariff exposure, evolving promotional tactics, and continued investment in growth channels. Tariff and cost management: Management expects tariff-related cost increases to have a more significant impact in the second half of the year. The company is exploring supply chain efficiencies, vendor negotiations, and expense controls to minimize these effects, while remaining cautious about passing costs to customers through price increases. International and B2B expansion: The company plans to accelerate growth in international markets by launching in Japan and South Korea and investing in localization efforts. Expansion of the B2B 'TEAMS' business is also a priority, with new leadership and outbound sales initiatives aimed at capturing institutional apparel contracts. Retail and community engagement: Figs is investing in physical retail, with new Community Hub store openings planned. Management expects these locations to attract new customers and strengthen brand loyalty, noting that a significant proportion of store visitors are new to the brand and that many transition to omnichannel purchasing. In upcoming quarters, the StockStory team will focus on (1) the pace and success of international expansion, including new market entries in Japan and South Korea, (2) the effectiveness of cost mitigation efforts as tariff pressures build in the second half of the year, and (3) progress in scaling the B2B TEAMS business and physical retail footprint. Additional attention will be paid to customer retention metrics and the impact of evolving promotional strategies. Figs currently trades at a forward P/E ratio of 67.2×. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
6 days ago
- Business
- Business Wire
FIGS Announces Participation in the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference
SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today announced that Trina Spear, Chief Executive Officer and Co-Founder, and Sarah Oughtred, Chief Financial Officer, are scheduled to participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference on Tuesday, June 10, 2025, at 11:15 a.m. ET. The audio portion of the fireside chat will be webcast live over the internet and can be accessed at An online archive will be available on that site for a period of 90 days following the fireside chat. About FIGS FIGS is a founder-led, direct-to-consumer healthcare apparel and lifestyle brand that seeks to celebrate, empower and serve current and future generations of healthcare professionals. We create technically advanced apparel and products that feature an unmatched combination of comfort, durability, function and style. We share stories about healthcare professionals' experiences in ways that inspire them. We build meaningful connections within the healthcare community that we created. Above all, we seek to make an impact for our community, including by advocating for them and always having their backs. We serve healthcare professionals in numerous countries in North America, Europe, the Asia Pacific region and the Middle East. We also serve healthcare institutions through our TEAMS platform.
Yahoo
20-05-2025
- Business
- Yahoo
1 Safe-and-Steady Stock on Our Buy List and 2 to Ignore
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. Luckily for you, StockStory helps you navigate which companies are truly worth holding. That said, here is one low-volatility stock providing safe-and-steady growth and two stuck in limbo. Rolling One-Year Beta: -0.07 Best known for its Arm & Hammer baking soda, Church & Dwight (NYSE:CHD) is a household and personal care products company with a vast portfolio that spans laundry detergent to toothbrushes to hair removal creams. Why Are We Cautious About CHD? Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion Demand will likely fall over the next 12 months as Wall Street expects flat revenue Day-to-day expenses have swelled relative to revenue over the last year as its operating margin fell by 4.9 percentage points Church & Dwight is trading at $95.50 per share, or 25.5x forward P/E. Read our free research report to see why you should think twice about including CHD in your portfolio, it's free. Rolling One-Year Beta: 0.72 Rising to fame via TikTok and founded in 2013 by Heather Hasson and Trina Spear, Figs (NYSE:FIGS) is a healthcare apparel company known for its stylish approach to medical attire and uniforms. Why Is FIGS Not Exciting? Demand for its offerings was relatively low as its number of active customers has underwhelmed Incremental sales over the last five years were much less profitable as its earnings per share fell by 26.9% annually while its revenue grew Negative returns on capital show that some of its growth strategies have backfired At $4.43 per share, Figs trades at 61x forward P/E. Check out our free in-depth research report to learn more about why FIGS doesn't pass our bar. Rolling One-Year Beta: 0.61 Founded by a mother seeking treatment for her daughter's pulmonary arterial hypertension, United Therapeutics (NASDAQ:UTHR) develops and commercializes medications for chronic lung diseases and other life-threatening conditions, with a focus on pulmonary hypertension treatments. Why Do We Love UTHR? Impressive 22.9% annual revenue growth over the last two years indicates it's winning market share this cycle Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends Returns on capital are climbing as management makes more lucrative bets United Therapeutics's stock price of $303.40 implies a valuation ratio of 10.4x forward P/E. Is now the right time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free.
Fibre2Fashion
13-05-2025
- Business
- Fibre2Fashion
US' Figs' net revenues increase 4.7% to $124.9 mn in Q1 FY25
Insights Figs has reported Q1 net revenues of $124.9 million, up 4.7 per cent year-over-year, driven by higher AOV and returning US growth. Scrubwear and non-scrubwear revenues rose 4.9 per cent and 3.8 per cent, respectively. Gross margin declined to 67.6 per cent due to product mix and freight costs. Operating expenses rose 3.6 per cent but decreased as a percentage of revenue. The net revenues of American healthcare apparel company Figs were $124.9 million in the first quarter (Q1) of fiscal 2025 (FY25), an increase of 4.7 per cent year-over-year, primarily due to an increase in orders from existing customers and higher average order value (AOV). Scrubwear net revenues were $99.6 million, a rise of 4.9 per cent year-over-year. Non-scrubwear net revenues were $25.3 million, up by 3.8 per cent year-over-year. In the first quarter of fiscal 2025, US net revenues were $106 million, an increase of 2.9 per cent year-over-year. International net revenues were $18.9 million, an increase of 16.4 per cent year-over-year. Figs has reported Q1 net revenues of $124.9 million, up 4.7 per cent year-over-year, driven by higher AOV and returning US growth. Scrubwear and non-scrubwear revenues rose 4.9 per cent and 3.8 per cent, respectively. Gross margin declined to 67.6 per cent due to product mix and freight costs. Operating expenses rose 3.6 per cent but decreased as a percentage of revenue. Gross margin was 67.6 per cent, a decrease of 130 basis points year-over-year, primarily due to product mix shift and higher freight expense, partially offset by a lower mix of promotional sales. Operating expenses were $84.7 million, an increase of 3.6 per cent year-over-year. As a percentage of net revenues, operating expenses decreased to 67.8 per cent from 68.5 per cent in the same period last year, primarily due to lower stock-based compensation expense, partially offset by higher operational costs at the new fulfilment centre, higher shipping costs, and higher depreciation, the company said in a press release. 'First quarter results were ahead of expectations, supported by customer growth, strong full-priced selling, record AOV, and ultimately, a return to growth in the US,' said Trina Spear, chief executive officer and co-founder. 'These positive signs bolster our conviction that the industry is on the path to normalisation and our actions are resonating. At the same time, we are also operating in a period of growing economic uncertainty, where we believe we have an opportunity to demonstrate our category leadership, build upon our competitive advantages, and leverage our incredibly strong balance sheet. We are maintaining the clear focus that we outlined at the beginning of the year – our unwavering efforts to serve our community and our intent to accelerate investment to better support our opportunity. We believe great brands uniquely harness adversity, and we will continue to boldly lead and define this industry going forward.' 'While 2025 started on a strong note, changes in US trade policies have added greater variability to our planning, particularly in the second half of the year. As we continue to evaluate a range of scenarios, our updated 2025 outlook reflects the projected impact of the current tariff structure, excluding the currently-paused reciprocal tariffs. We are determined to remain diligent and nimble in navigating this challenging environment, prudently planning our business while continuing our steadfast focus of serving those who serve others,' Sarah Oughtred, chief financial officer, said. Fibre2Fashion News Desk (RR) Disclaimer - All News/Articles items are subject to copyright and no article either in full or part may be reproduced in any form without permission from Fibre2Fashion Pvt. Ltd. Disclaimer - All News/Articles items are subject to copyright and no article either in full or part may be reproduced in any form without permission from Fibre2Fashion Pvt. Ltd.
Yahoo
08-05-2025
- Business
- Yahoo
Figs's (NYSE:FIGS) Q1: Strong Sales But Stock Drops 13.4%
Healthcare apparel company Figs (NYSE:FIGS) beat Wall Street's revenue expectations in Q1 CY2025, with sales up 4.7% year on year to $124.9 million. Its GAAP profit of $0.01 per share was $0.01 above analysts' consensus estimates. Is now the time to buy Figs? Find out in our full research report. Revenue: $124.9 million vs analyst estimates of $119.2 million (4.7% year-on-year growth, 4.8% beat) EPS (GAAP): $0.01 vs analyst estimates of $0 ($0.01 beat) Adjusted EBITDA: $9.00 million vs analyst estimates of $8.00 million (7.2% margin, 12.5% beat) Operating Margin: -0.2%, in line with the same quarter last year Free Cash Flow Margin: 6.3%, down from 9.3% in the same quarter last year Active Customers: 2.7 million, up 99,000 year on year Market Capitalization: $794.7 million 'First quarter results were ahead of expectations, supported by customer growth, strong full-priced selling, record AOV, and ultimately, a return to growth in the U.S.,' said Trina Spear, Chief Executive Officer and Co-Founder. Rising to fame via TikTok and founded in 2013 by Heather Hasson and Trina Spear, Figs (NYSE:FIGS) is a healthcare apparel company known for its stylish approach to medical attire and uniforms. A company's long-term sales performance can indicate its overall quality. Any business can have short-term success, but a top-tier one grows for years. Luckily, Figs's sales grew at an incredible 37.3% compounded annual growth rate over the last five years. Its growth beat the average consumer discretionary company and shows its offerings resonate with customers. We at StockStory place the most emphasis on long-term growth, but within consumer discretionary, a stretched historical view may miss a company riding a successful new product or trend. Figs's recent performance shows its demand has slowed significantly as its annualized revenue growth of 4.3% over the last two years was well below its five-year trend. Figs also discloses its number of active customers, which reached 2.7 million in the latest quarter. Over the last two years, Figs's active customers averaged 9.9% year-on-year growth. Because this number is higher than its revenue growth during the same period, we can see the company's monetization has fallen. This quarter, Figs reported modest year-on-year revenue growth of 4.7% but beat Wall Street's estimates by 4.8%. Looking ahead, sell-side analysts expect revenue to decline by 2.2% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and suggests its products and services will face some demand challenges. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Figs's operating margin has shrunk over the last 12 months and averaged 3% over the last two years. Although this result isn't good, the company's elite historical revenue growth suggests it ramped up investments to capture market share. We'll keep a close eye to see if this strategy pays off. In Q1, Figs's breakeven margin was in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Figs's full-year EPS dropped 259%, or 37.6% annually, over the last four years. We tend to steer our readers away from companies with falling revenue and EPS, where diminishing earnings could imply changing secular trends and preferences. Consumer Discretionary companies are particularly exposed to this, and if the tide turns unexpectedly, Figs's low margin of safety could leave its stock price susceptible to large downswings. In Q1, Figs reported EPS at $0.01, in line with the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Figs to perform poorly. Analysts forecast its full-year EPS of $0.02 will hit $0.07. The quarter itself was fine, with revenue and EBITDA beating. However, full-year EBITDA margin guidance missed and likely raises fears of tariff or macro impacts. The stock traded down 13.4% to $4.35 immediately after reporting. Should you buy the stock or not? When making that decision, it's important to consider its valuation, business qualities, as well as what has happened in the latest quarter. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
